Coagulation

Coagulation is a change of physical state of the blood due to the conversion of a soluble plasma protein, fibrinogen, into a solid gel, fibrin. The management and control of anticoagulant therapy and the assessment of pre and post surgical states, among others requires a proper evaluation of the coagulation cascade. Several tests help the physician in the diagnosis of alterate coagulation states and management of coagulopathy. The coagulation reagents have been specifically validated to Biosystems coagulometers. Calibrator and Controls The Coagulation Calibrator is a lyophilized pooled human plasma containing component concentrations suitable for the calibration of measurement procedures. The Coagulation Control is a lyophilized human plasma with stabilizer suitable for the quality control of the clinical laboratories. The product is intended for intralaboratory quality control purposes only and is supplied with intervals of suggested acceptable values. Presentation Code APTT 4x4 mL 61004 APTT B (CaCl 2 ) 4x16 mL 61005 APTT (4x4 mL+1x16 mL) 61009 Presentation Code PT 4x5 mL 61001 Presentation Code Fib 4x2 mL 61002 Fib B (Imidazol) 4x15 mL 61003 Presentation Code Calibrator 4x1 mL 61006 Control I 4x1 mL 61007 Control II 4x1 mL 61008 Presentation Code TT 4x3 mL 61000 Prothrombin Time (PT) Principle of the method: The addition of calcium thromboplastin to plasma induces the formation of the fibrin clot. The method measures the clot formation time. Intended use: • Screening assay used to monitor oral anticoagulant therapy • It helps detect and diagnose a bleeding disorder Activated Partial Thromboplastin Time (APTT) Principle of the method: The addition of the phospholipid cephalin to plasma samples in the presence of calcium and an activator induces the formation of the fibrin clot. The method measures the clot formation time. Intended use: • Screening assay used in the monitoring of heparin therapy • As part of investigation of a possible bleeding disorder Fibrinogen Clauss Principle of the method: The Clauss method measures the rate of conversion of fibrinogen into fibrin in a diluted plasma in the presence of excess of thrombin. The measured clotting time is inversely proportional to fibrinogen concentration. Intended use: • As part of an investigation of a possible bleeding disorder or thrombotic episode • To help evaluate the risk of developing cardiovascular disease Thrombin Time (TT) Principle of the method: Additon of human thrombin to plasma samples induces de formation of fibrin clot. The method measures the clot formation time. Intended use: • To evaluate the level and function of fibrinogen • To detect heparin contamination • As part of investigation of a bleeding or thrombotic episode PROCEDURE APTTA 50 μ L APTTB CaCl 2 50 μ L Plasma 50 μ L Plasma 37 o C 3 min Plasma + APT CLOT PROCEDURE PT Reagent 100 μ L Plasma 50 μ L 2 min 37 o C Plasma CLOT PROCEDURE FIB (Human Thrombin) 50 μ L Diluted Plasma 1:10 100 μ L 2 min 37 o C Diluted Plasma CLOT PROCEDURE TT (Human Thrombin) 100 μ L Plasma 100 μ L 2 min 37 o C Plasma CLOT